Quotes: MENA   Enter Symbol: NewsLetter: Search: advanced

Server is busy please try again later.  Join our daily free Newsletter

MENAFN Press - 17/10/2012
No. of Ratings : 0
Add to Mixx!

Due to technical reasons, this story has been removed from our database.

About CytoDyn Inc
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. CytoDyn intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. CytoDyn recently completed a humanized antibody construct of Cytolin(R), filed a provisional patent for its use, and manufacturing discussions are underway. In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and CytoDyn please go to www.cytodyn.com.Forward-Looking StatementsThis press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.



  MENA News Headlines
 Oct 4 2015 - Qatar might not need to hike interest rates: Central Bank governorGulf Times
(MENAFN - Gulf Times) Qatar, whose currency is pegged to the dollar, may not necessarily increase the interest rates, following an anticipated lift-off by the US Federal Reserve later this year; ...

 Oct 4 2015 - Jelaiha intersection opens to trafficGulf Times
(MENAFN - Gulf Times) The Jelaiha intersection was recently opened to traffic, the Public Works Authority (Ashghal) has announced. The opening constitutes Phase 1 of upgrading Al Khafji Street and ...

 Oct 4 2015 - FM lays stress on right to educationGulf Times
(MENAFN - Gulf Times) HE the Foreign Minister Dr Khalid bin Mohamed al-Attiyah has stressed the need to prioritise the right to education as millions of children around the world are still deprived ...

 Oct 4 2015 - Qatar- ASPIRE4SPORT event starts tomorrowGulf Times
(MENAFN - Gulf Times) ASPIRE4SPORT Congress and Exhibition 2015 is an exclusive two-day event and networking session opens in Berlin tomorrow. The event features a Global Summit related to football ...

 Oct 4 2015 - OIC must intensify efforts to face challenges: QatarGulf Times
(MENAFN - Gulf Times) The Organisation of Islamic Co-operation (OIC) must intensify its efforts in the face of challenges faced by people in Palestine, Syria, Iraq, Libya and Yemen as well to fight ...

 Oct 4 2015 - Qatar- Yaris and Corolla cars recalledTweetGulf Times
(MENAFN - Gulf Times) The Ministry of Economy and Commerce (MEC), in collaboration with Abdullah Abdulghani & Bros Co (AAB), has announced a recall of 2003-2007 Toyota Yaris and Corolla models due to ...

 Oct 4 2015 - Qatar- Meeting on women, crime preventionGulf Times
(MENAFN - Gulf Times) Qatar's Permanent Mission to the UN, in collaboration with Italy, Thailand, and the UN Office on Drugs and Crime (UNODC) hosted a meeting on "Women, Crime Prevention, Criminal ...

 Oct 4 2015 - Qatar- SEC renews school robotics programmeGulf Times
(MENAFN - Gulf Times) The Supreme Education Council (SEC) has signed a Memorandum of Understanding (MoU) with Maersk Oil Qatar (MOQ), the College of North Atlantic-Qatar (CNA-Q) and Qatar Petroleum ...

 Oct 4 2015 - Stars of Science shortlists innovators for 7th seasonGulf Times
(MENAFN - Gulf Times) Stars of Science, Qatar Foundation for Education, Science and Community Development (QF)'s "edutainment reality" TV programme on MBC4 that encourages science, technology and ...

 Oct 4 2015 - Qatar- QU college hosts delegates from LNG Japan, RasGasGulf Times
(MENAFN - Gulf Times) Qatar University College of Education (QU-CED) recently hosted a visit by a six-member delegation from LNG Corporation (LNG Japan) and RasGas Company Limited (RasGas).QU ...




Click to Apply


Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  

Middle East North Africa - Financial Network

Main News
News By Industry
News By Country

Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices


Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks

Saudi Arabia 

Economic Calendar
Financial Glossary

Financial Calculators

RSS Feeds [XML]

Corporate Monitor


Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters

© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help